<article article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15986036</article-id><article-id pub-id-type="pmc">2361554</article-id><article-id pub-id-type="pii">6602640</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602640</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Di Costanzo</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Carlini</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Doni</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massidda</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mattioli</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Iop</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barletta</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Moscetti</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Recchia</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Tralongo</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Gasperoni</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>U.O di Oncologia Medica, Azienda Ospedaliera Careggi, Via Pieraccini 17, Florence, Italy</aff><aff id="aff2"><label>2</label>U.O di Oncologia Medica A, Polo Oncologico S Raffaele Regina Elena, Roma, Italy</aff><aff id="aff3"><label>3</label>Oncologia Medica, Policlinico Universitario, Cagliari, Italy</aff><aff id="aff4"><label>4</label>U.O di Oncologia Medica, Ospedale S Croce, Fano, Italy</aff><aff id="aff5"><label>5</label>Servizio di Oncologia, Ospedale di Latisana, Udine, Italy</aff><aff id="aff6"><label>6</label>Oncologia B, Istituto Nazionale Tumori Pascale, Napoli, Italy</aff><aff id="aff7"><label>7</label>Oncologia Medica, policlinico Umberto I, Roma, Italy</aff><aff id="aff8"><label>8</label>U.O di Oncologia Medica, Ospedale di Avezzano, Italy</aff><aff id="aff9"><label>9</label>U.O di oncologia Medica, Ospedale G Di Maria, Avola, Siracusa, Italy</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:dicostanzofrancesco@tiscali.it">dicostanzofrancesco@tiscali.it</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>06</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>19</day><month>07</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>25</day><month>07</month><year>2005</year></pub-date><volume>93</volume><issue>2</issue><fpage>185</fpage><lpage>189</lpage><history><date date-type="received"><day>21</day><month>01</month><year>2005</year></date><date date-type="rev-recd"><day>06</day><month>04</month><year>2005</year></date><date date-type="accepted"><day>08</day><month>04</month><year>2005</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p><offsets xml_i="4533" xml_f="4665" txt_i="11" txt_f="143">This study was performed to determine the activity of adding continuous infusion (CI) of 5-fluorouracil (5-FU) to gemcitabine (GEM) </offsets><italic><offsets xml_i="4673" xml_f="4675" txt_i="143" txt_f="145">vs</offsets></italic><offsets xml_i="4684" xml_f="4827" txt_i="145" txt_f="288"> GEM alone in advanced pancreatic cancer (APC). In all, 94 chemo-naïve patients with APC were randomised to receive GEM alone (arm A: 1000 mg m</offsets><sup><offsets xml_i="4832" xml_f="4834" txt_i="288" txt_f="290">−2</offsets></sup><offsets xml_i="4840" xml_f="5009" txt_i="290" txt_f="459"> per week for 7 weeks followed by a 2 week rest period, then weekly for 3 consecutive weeks out of every 4 weeks) or in combination with CI 5-FU (arm B: CI 5-FU 200 mg m</offsets><sup><offsets xml_i="5014" xml_f="5016" txt_i="459" txt_f="461">−2</offsets></sup><offsets xml_i="5022" xml_f="5026" txt_i="461" txt_f="465"> day</offsets><sup><offsets xml_i="5031" xml_f="5033" txt_i="465" txt_f="467">−1</offsets></sup><offsets xml_i="5039" xml_f="5882" txt_i="467" txt_f="1310"> for 6 weeks followed by a 2 week rest period, then for 3 weeks every 4 weeks). Overall response rate (RR) was the primary end point and criteria for decision were planned according to the Simon's optimal two-stage design. The overall RR was 8% (arm A) and 11% (arm B) (95% confidence interval: 0.5–16% and 2–22%), respectively, and stable disease was 29 and 28%. The median duration of RR was 34 weeks (range 25–101 weeks) for GEM and 26 weeks (range 16–46 weeks) for the combination. The median progression-free survival (PFS) was 14 weeks (range 2–65 weeks) and 18 weeks (range 4–51 weeks), respectively. The median overall survival (OS) was 31 weeks (range 1–101 weeks) and 30 weeks (1–101 weeks). Toxicity was mild in both arms. This study does not show promising activity in terms of RR, PFS and OS for the double combination arm in APC.</offsets></p></abstract><kwd-group><kwd>5-FU</kwd><kwd>gemcitabine</kwd><kwd>advanced pancreatic cancer</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="6026" xml_f="6221" txt_i="1318" txt_f="1513">Pancreatic cancer is the fifth most common cancer worldwide. Unfortunately, most patients have locally advanced or metastatic pancreatic cancer and usually are poorly responsive to chemotherapy (</offsets><xref ref-type="other" rid="bib10"><offsets xml_i="6256" xml_f="6265" txt_i="1513" txt_f="1522">Greenlee </offsets><italic><offsets xml_i="6273" xml_f="6278" txt_i="1522" txt_f="1527">et al</offsets></italic><offsets xml_i="6287" xml_f="6293" txt_i="1527" txt_f="1533">, 2001</offsets></xref><offsets xml_i="6300" xml_f="6433" txt_i="1533" txt_f="1666">). Randomised studies have revealed a significant better overall survival (OS) with chemotherapy against best supportive care (BSC) (</offsets><xref ref-type="other" rid="bib32"><offsets xml_i="6468" xml_f="6498" txt_i="1666" txt_f="1696">Weinerman and MacCormick, 1994</offsets></xref><offsets xml_i="6505" xml_f="6507" txt_i="1696" txt_f="1698">; </offsets><xref ref-type="other" rid="bib9"><offsets xml_i="6541" xml_f="6551" txt_i="1698" txt_f="1708">Glimelius </offsets><italic><offsets xml_i="6559" xml_f="6564" txt_i="1708" txt_f="1713">et al</offsets></italic><offsets xml_i="6573" xml_f="6579" txt_i="1713" txt_f="1719">, 1996</offsets></xref><offsets xml_i="6586" xml_f="6863" txt_i="1719" txt_f="1996">). Although the increase in median survival was modest: 4 and 6 months for the treatment group as compared with 3 and 2.5 months for BSC, respectively, various schedules and different regimens have been evaluated with no proven benefit over single-agent 5-fluorouracil (5-FU) (</offsets><xref ref-type="other" rid="bib8"><offsets xml_i="6897" xml_f="6906" txt_i="1996" txt_f="2005">Cullinan </offsets><italic><offsets xml_i="6914" xml_f="6919" txt_i="2005" txt_f="2010">et al</offsets></italic><offsets xml_i="6928" xml_f="6934" txt_i="2010" txt_f="2016">, 1985</offsets></xref><offsets xml_i="6941" xml_f="6943" txt_i="2016" txt_f="2018">; </offsets><xref ref-type="other" rid="bib7"><offsets xml_i="6977" xml_f="6986" txt_i="2018" txt_f="2027">Cullinan </offsets><italic><offsets xml_i="6994" xml_f="6999" txt_i="2027" txt_f="2032">et al</offsets></italic><offsets xml_i="7008" xml_f="7014" txt_i="2032" txt_f="2038">, 1990</offsets></xref><offsets xml_i="7021" xml_f="7165" txt_i="2038" txt_f="2182">). In advanced pancreatic cancer (APC), continuous infusion (CI) of 5-FU is superior to 5-FU bolus in terms of response rate (RR) and toxicity (</offsets><xref ref-type="other" rid="bib12"><offsets xml_i="7200" xml_f="7207" txt_i="2182" txt_f="2189">Hansen </offsets><italic><offsets xml_i="7215" xml_f="7220" txt_i="2189" txt_f="2194">et al</offsets></italic><offsets xml_i="7229" xml_f="7235" txt_i="2194" txt_f="2200">, 1988</offsets></xref><offsets xml_i="7242" xml_f="7244" txt_i="2200" txt_f="2202">; </offsets><xref ref-type="other" rid="bib14"><offsets xml_i="7279" xml_f="7287" txt_i="2202" txt_f="2210">Hidalgo </offsets><italic><offsets xml_i="7295" xml_f="7300" txt_i="2210" txt_f="2215">et al</offsets></italic><offsets xml_i="7309" xml_f="7315" txt_i="2215" txt_f="2221">, 1999</offsets></xref><offsets xml_i="7322" xml_f="7324" txt_i="2221" txt_f="2223">).</offsets></p><p><offsets xml_i="7331" xml_f="7452" txt_i="2224" txt_f="2345">Gemcitabine (GEM), a deoxycitidine analogue, has demonstrated activity in APC in terms of clinical benefit and survival (</offsets><xref ref-type="other" rid="bib25"><offsets xml_i="7487" xml_f="7498" txt_i="2345" txt_f="2356">Rothenberg </offsets><italic><offsets xml_i="7506" xml_f="7511" txt_i="2356" txt_f="2361">et al</offsets></italic><offsets xml_i="7520" xml_f="7526" txt_i="2361" txt_f="2367">, 1996</offsets></xref><offsets xml_i="7533" xml_f="7567" txt_i="2367" txt_f="2401">). A phase III trial compared GEM </offsets><italic><offsets xml_i="7575" xml_f="7577" txt_i="2401" txt_f="2403">vs</offsets></italic><offsets xml_i="7586" xml_f="7679" txt_i="2403" txt_f="2496"> 5-FU alone, the GEM arm showed a statistically longer survival and better clinical benefit (</offsets><xref ref-type="other" rid="bib4"><offsets xml_i="7713" xml_f="7720" txt_i="2496" txt_f="2503">Burris </offsets><italic><offsets xml_i="7728" xml_f="7733" txt_i="2503" txt_f="2508">et al</offsets></italic><offsets xml_i="7742" xml_f="7748" txt_i="2508" txt_f="2514">, 1997</offsets></xref><offsets xml_i="7755" xml_f="7969" txt_i="2514" txt_f="2728">). Phase I and II trials of GEM plus 5-FU bolus reported interesting results in terms of clinical benefit (38–66%). Recently, Eastern Cooperative Oncology Group (ECOG) randomised patients with APC to 5-FU plus GEM </offsets><italic><offsets xml_i="7977" xml_f="7979" txt_i="2728" txt_f="2730">vs</offsets></italic><offsets xml_i="7988" xml_f="8067" txt_i="2730" txt_f="2809"> GEM alone. The OS was better, but not significant in the combination arm (6.7 </offsets><italic><offsets xml_i="8075" xml_f="8077" txt_i="2809" txt_f="2811">vs</offsets></italic><offsets xml_i="8086" xml_f="8099" txt_i="2811" txt_f="2824"> 5.4 months; </offsets><italic><offsets xml_i="8107" xml_f="8108" txt_i="2824" txt_f="2825">P</offsets></italic><offsets xml_i="8117" xml_f="8377" txt_i="2825" txt_f="3085">=0.09) and grade 3 and 4 leukopenia, thrombocytopenia and diarrhoea was higher in the combination arm. Several combination regimens with 5-FU, cisplatin, capecitabine, irinotecan, oxaliplatin, premetrexed and docetaxel were developed without a sure advantage (</offsets><xref ref-type="other" rid="bib5"><offsets xml_i="8411" xml_f="8422" txt_i="3085" txt_f="3096">Cartwright </offsets><italic><offsets xml_i="8430" xml_f="8435" txt_i="3096" txt_f="3101">et al</offsets></italic><offsets xml_i="8444" xml_f="8450" txt_i="3101" txt_f="3107">, 2002</offsets></xref><offsets xml_i="8457" xml_f="8459" txt_i="3107" txt_f="3109">; </offsets><xref ref-type="other" rid="bib15"><offsets xml_i="8494" xml_f="8507" txt_i="3109" txt_f="3122">Kindler, 2002</offsets></xref><offsets xml_i="8514" xml_f="8516" txt_i="3122" txt_f="3124">; </offsets><xref ref-type="other" rid="bib18"><offsets xml_i="8551" xml_f="8556" txt_i="3124" txt_f="3129">Lutz </offsets><italic><offsets xml_i="8564" xml_f="8569" txt_i="3129" txt_f="3134">et al</offsets></italic><offsets xml_i="8578" xml_f="8584" txt_i="3134" txt_f="3140">, 2002</offsets></xref><offsets xml_i="8591" xml_f="8593" txt_i="3140" txt_f="3142">; </offsets><xref ref-type="other" rid="bib26"><offsets xml_i="8628" xml_f="8637" txt_i="3142" txt_f="3151">Schilsky </offsets><italic><offsets xml_i="8645" xml_f="8650" txt_i="3151" txt_f="3156">et al</offsets></italic><offsets xml_i="8659" xml_f="8665" txt_i="3156" txt_f="3162">, 2002</offsets></xref><offsets xml_i="8672" xml_f="8674" txt_i="3162" txt_f="3164">; </offsets><xref ref-type="other" rid="bib22"><offsets xml_i="8709" xml_f="8734" txt_i="3164" txt_f="3189">Pizzolato and Saltz, 2003</offsets></xref><offsets xml_i="8741" xml_f="8743" txt_i="3189" txt_f="3191">; </offsets><xref ref-type="other" rid="bib27"><offsets xml_i="8778" xml_f="8788" txt_i="3191" txt_f="3201">Schneider </offsets><italic><offsets xml_i="8796" xml_f="8801" txt_i="3201" txt_f="3206">et al</offsets></italic><offsets xml_i="8810" xml_f="8816" txt_i="3206" txt_f="3212">, 2003</offsets></xref><offsets xml_i="8823" xml_f="8825" txt_i="3212" txt_f="3214">).</offsets></p><p><offsets xml_i="8832" xml_f="8979" txt_i="3215" txt_f="3362">The current multicentre randomised phase II study was started to investigate the feasibility and activity of the combination with GEM plus CI 5-FU </offsets><italic><offsets xml_i="8987" xml_f="8989" txt_i="3362" txt_f="3364">vs</offsets></italic><offsets xml_i="8998" xml_f="9237" txt_i="3364" txt_f="3603"> GEM alone in patients with APC. The rationale of the combination of 5-FU with CI and GEM is to prolong thymidylate synthetase inhibition, increasing the chance of pharmacodynamic with GEM and to reduce toxicity with respect to 5-FU bolus.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="9282" xml_f="9303" txt_i="3604" txt_f="3625">MATERIALS AND METHODS</offsets></title><sec><title><offsets xml_i="9323" xml_f="9342" txt_i="3626" txt_f="3645">Patient eligibility</offsets></title><p><offsets xml_i="9353" xml_f="9824" txt_i="3646" txt_f="4114">The following inclusion criteria were mandatory to the study: histological or cytological diagnosis of APC (locally advanced or metastatic) with bidimensionally measurable disease. Patients were not amenable to surgery or radiotherapy. Karnofsky performance status (KPS) was 50 or greater, age between 18 and 75 years, no prior chemotherapy, no central nervous system metastases, life expectancy of at least 3 months, adequate haematological (neutrophil count &gt;1500 dl</offsets><sup><offsets xml_i="9829" xml_f="9831" txt_i="4114" txt_f="4116">−1</offsets></sup><offsets xml_i="9837" xml_f="9868" txt_i="4116" txt_f="4144">; platelet count &gt;100 000 dl</offsets><sup><offsets xml_i="9873" xml_f="9875" txt_i="4144" txt_f="4146">−1</offsets></sup><offsets xml_i="9881" xml_f="10166" txt_i="4146" txt_f="4422">), renal (serum creatinine &lt;1.5 × the upper limit of normal (ULN) value) and hepatic (alkaline phosphatase &lt;3 × ULN value and bilirubin &lt;1.5 × ULN value) functions. The protocol was approved by the Ethical Committee and written informed consent was obtained from all patients.</offsets></p></sec><sec><title><offsets xml_i="10188" xml_f="10202" txt_i="4424" txt_f="4438">Treatment plan</offsets></title><p><offsets xml_i="10213" xml_f="10353" txt_i="4439" txt_f="4579">Patients were centrally randomised by the central office of the Italian Oncology Group for Clinical Research (GOIRC) to receive: GEM alone (</offsets><italic><offsets xml_i="10361" xml_f="10366" txt_i="4579" txt_f="4584">arm A</offsets></italic><offsets xml_i="10375" xml_f="10409" txt_i="4584" txt_f="4618">) or in combination with CI 5-FU (</offsets><italic><offsets xml_i="10417" xml_f="10422" txt_i="4618" txt_f="4623">arm B</offsets></italic><offsets xml_i="10431" xml_f="10532" txt_i="4623" txt_f="4724">). GEM was administered in both arms as a 30-min intravenous (i.v.) infusion at the dose of 1000 mg m</offsets><sup><offsets xml_i="10537" xml_f="10539" txt_i="4724" txt_f="4726">−2</offsets></sup><offsets xml_i="10545" xml_f="10741" txt_i="4726" txt_f="4922"> once per week for 7 weeks, followed by 2 weeks of rest. Thereafter, GEM was administered once weekly for 3 consecutive weeks out of every 4 weeks. In arm B, GEM was combined with CI 5-FU 200 mg m</offsets><sup><offsets xml_i="10746" xml_f="10748" txt_i="4922" txt_f="4924">−2</offsets></sup><offsets xml_i="10754" xml_f="10758" txt_i="4924" txt_f="4928"> day</offsets><sup><offsets xml_i="10763" xml_f="10765" txt_i="4928" txt_f="4930">−1</offsets></sup><offsets xml_i="10771" xml_f="10918" txt_i="4930" txt_f="5077"> i.v. for 6 weeks in the first cycle, followed by a week of rest and then for 3 weeks every 4 weeks. All patients were treated on outpatient basis.</offsets></p></sec><sec><title><offsets xml_i="10940" xml_f="10990" txt_i="5079" txt_f="5129">Pretreatment evaluation and assessment of efficacy</offsets></title><p><offsets xml_i="11001" xml_f="12657" txt_i="5130" txt_f="6786">At screening, all patients were evaluated with physical examination, complete blood count with leucocyte differential count, serum creatinine, bilirubin, transaminase, and alkaline phosphatase, serum tumour marker (CEA and Ca 19-9) levels, ECG and computed tomography (CT) scan of chest, abdomen and pelvis of all tumour sites. During the study, patients were monitored before each cycle for medical history, physical evaluation, clinical benefit, serum chemistry and tumour markers, and evaluated for toxicity. The RR (WHO) were assessed every 2 months or earlier if clinically indicated. If a response was documented, treatment continued until progression. Clinical evaluation of response was not used. Pleural effusion, ascites and hepatomegaly were not used for response assessment. In the case of grade 2 nonhaematological toxicity or greater, patients received symptomatic therapy and 5-FU therapy was stopped until the toxicity ceased and the dose was reduced in the next cycle as follows: in the case of grade 2 stomatitis, diarrhoea or HFS, dose reduction was about 25% of planned dose; in the case of grade 3 stomatitis, diarrhoea or HFS, dose reduction of 5-FU was 50%; and in the case of grade 4 stomatitis, diarrhoea or HFS, 5-FU and GEM therapy was discontinued. In the case of grade 2 haematological toxicity, GEM dose was reduced by 25%; in the case of grade 3, dose reduction was 50%; patientsdiscontinued from therapy when treatment was associated with grade 4 neutropenia and infection. Patients before each cycle received a diary for evaluation of quality of life (QoL), according to Subjective Chemotherapy Impact (SCI) questionnaire (</offsets><xref ref-type="other" rid="bib31"><offsets xml_i="12692" xml_f="12702" txt_i="6786" txt_f="6796">Tamburini </offsets><italic><offsets xml_i="12710" xml_f="12715" txt_i="6796" txt_f="6801">et al</offsets></italic><offsets xml_i="12724" xml_f="12730" txt_i="6801" txt_f="6807">, 1991</offsets></xref><offsets xml_i="12737" xml_f="13084" txt_i="6807" txt_f="7154">). The questionnaire allowed us to assess the duration of physical and psychological discomfort of patients during the treatment. The questionnaire consisted of two items: (1) how many disturbed days did you have during the treatment?; (2) how many days do you want to cancel during the treatment? The questionnaire was answered before each cycle.</offsets></p></sec><sec><title><offsets xml_i="13106" xml_f="13132" txt_i="7156" txt_f="7182">Statistical considerations</offsets></title><p><offsets xml_i="13143" xml_f="14619" txt_i="7183" txt_f="8659">Primary end points of this study were RR. Secondary objectives were to assess the OS, safety and tolerability of the regimens. Overall survival was calculated from the first day of treatment until the date of death. Patients alive at the end of study were censored at last observation visit. For progression-free survival (PFS), the last date PFS was the date of progression or death (if dead without progression). Patients not experiencing progression or death were censored at last observation visit. Progression-free survival and OS were described according to the Kaplan–Meier method. Descriptive statistics formed the primary basis of analysis for the data collected in this study. The study was not powered for a formal comparison of efficacy outcome measures, and these were not performed. For each arm, a Simon's optimal two-stage design was chosen. According to this approach, the expected sample size is minimised for the first stage if the regimen has low activity. It was considered that the minimum RR had to be at least 10% and combination would had been investigated further if it showed an RR of 25% or more. Alpha and beta errors were fixed at 5 and 20%, respectively. According to these assumptions, 18 patients per arm had to be recruited in the first step if at least two responses were observed, then a further 25 patients would have been enrolled, up to a total of 43 patients per arm. A minimum of eight responses was defined in order to claim activity.</offsets></p></sec></sec><sec><title><offsets xml_i="14647" xml_f="14654" txt_i="8662" txt_f="8669">RESULTS</offsets></title><sec><title><offsets xml_i="14674" xml_f="14694" txt_i="8670" txt_f="8690">Patient demographics</offsets></title><p><offsets xml_i="14705" xml_f="14815" txt_i="8691" txt_f="8801">After 30 months of accrual, 94 patients were enrolled into this trial and their characteristics are listed in </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="14849" xml_f="14856" txt_i="8801" txt_f="8808">Table 1</offsets></xref><offsets xml_i="14863" xml_f="14935" txt_i="8808" txt_f="8880">. Three patients were ineligible due to nonpathologic diagnosis of APC (</offsets><italic><offsets xml_i="14943" xml_f="14944" txt_i="8880" txt_f="8881">n</offsets></italic><offsets xml_i="14953" xml_f="14993" txt_i="8881" txt_f="8921">=1), synchronous second primary tumour (</offsets><italic><offsets xml_i="15001" xml_f="15002" txt_i="8921" txt_f="8922">n</offsets></italic><offsets xml_i="15011" xml_f="15060" txt_i="8922" txt_f="8971">=1) and nonmeasurable disease: pleural effusion (</offsets><italic><offsets xml_i="15068" xml_f="15069" txt_i="8971" txt_f="8972">n</offsets></italic><offsets xml_i="15078" xml_f="15456" txt_i="8972" txt_f="9347">=1). The two arms of treatment were well balanced for prognostic factors. The median age was 63 years (range: 34–75 years). The KPS was ⩾80 in 62 patients (68%) and &lt;80 in 29 patients (32%). In the GEM arm, 35 patients (73%) had metastatic disease and 29 patients (67%) in the combination. In all, 48 patients (53%) had primary pancreatic tumour plus metastases in the liver.</offsets></p></sec><sec><title><offsets xml_i="15478" xml_f="15486" txt_i="9349" txt_f="9357">Toxicity</offsets></title><p><offsets xml_i="15497" xml_f="15758" txt_i="9358" txt_f="9619">A total of 253 cycles of chemotherapy were administered and the median number of cycles was 2 (range: 1–6). In all, 90 patients in both arms were evaluable for toxicity. The data toxicity of four patients were missing. The most common side effects are shown in </offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="15792" xml_f="15799" txt_i="9619" txt_f="9626">Table 2</offsets></xref><offsets xml_i="15806" xml_f="15949" txt_i="9626" txt_f="9769">. Both chemotherapy regimens were well tolerated. The principal differences between the two regimens were grade 1 and 2 mucositis (arm A/B: 14 </offsets><italic><offsets xml_i="15957" xml_f="15959" txt_i="9769" txt_f="9771">vs</offsets></italic><offsets xml_i="15968" xml_f="15991" txt_i="9771" txt_f="9794"> 29%) and diarrhoea (4 </offsets><italic><offsets xml_i="15999" xml_f="16001" txt_i="9794" txt_f="9796">vs</offsets></italic><offsets xml_i="16010" xml_f="16121" txt_i="9796" txt_f="9907"> 20%). One patient in the combination arm had grade 4 thrombocytopenia. There were no treatment-related deaths.</offsets></p></sec><sec><title><offsets xml_i="16143" xml_f="16176" txt_i="9909" txt_f="9942">Tumour response, PFS and survival</offsets></title><p><offsets xml_i="16187" xml_f="16452" txt_i="9943" txt_f="10208">In total, 91 patients were evaluable for response: 48 (98%) and 43 (96%) patients in arms A and B, respectively. Two RR were obtained in the first stage of study according to statistical considerations. The OR rate was 9.9%, with a total of nine partial responses (</offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="16486" xml_f="16493" txt_i="10208" txt_f="10215">Table 3</offsets></xref><offsets xml_i="16500" xml_f="17034" txt_i="10215" txt_f="10749">). There were no complete responses observed in this study. In the patients treated with GEM alone, the overall RR was 8% (95% confidence interval, 0.5–16%), while in the combination arm, it was 11% (95% confidence interval, 2–22%). The median duration of response was 34 weeks for GEM and 26 weeks for CI 5-FU+GEM. The median PFS was 14 weeks (range: 2–65 weeks) in the GEM arm alone and 18 weeks (range: 4–51 weeks) in the combination arm. Treatment with CI 5-FU plus GEM obtained a median OS of 31 weeks and 30 weeks in GEM alone (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="17066" xml_f="17074" txt_i="10749" txt_f="10757">Figure 1</offsets></xref><offsets xml_i="17081" xml_f="17335" txt_i="10757" txt_f="11011">). In all, 18% (arm A) and 20% (arm B) of patients survived over 12 months. Patients were evaluated before each cycle with QoL by SCI questionnaire. The analysis of the first cycles of treatment showed no significant increase of mean disturbed days (6.3 </offsets><italic><offsets xml_i="17343" xml_f="17345" txt_i="11011" txt_f="11013">vs</offsets></italic><offsets xml_i="17354" xml_f="17438" txt_i="11013" txt_f="11097"> 4.8) and mean of days that patients would like to cancel during the treatment (4.2 </offsets><italic><offsets xml_i="17446" xml_f="17448" txt_i="11097" txt_f="11099">vs</offsets></italic><offsets xml_i="17457" xml_f="17559" txt_i="11099" txt_f="11201"> 3.0) in the GEM alone and recombination arm. In the second cycle, the mean of disturbed days was 4.2 </offsets><italic><offsets xml_i="17567" xml_f="17569" txt_i="11201" txt_f="11203">vs</offsets></italic><offsets xml_i="17578" xml_f="17606" txt_i="11203" txt_f="11231"> 3.0 and cancelled days 0.2 </offsets><italic><offsets xml_i="17614" xml_f="17616" txt_i="11231" txt_f="11233">vs</offsets></italic><offsets xml_i="17625" xml_f="17644" txt_i="11233" txt_f="11252"> 1.2, respectively.</offsets></p></sec></sec><sec><title><offsets xml_i="17672" xml_f="17682" txt_i="11255" txt_f="11265">DISCUSSION</offsets></title><p><offsets xml_i="17693" xml_f="17985" txt_i="11266" txt_f="11558">Despite an increasing understanding of biology, diagnostic technology and introduction of new drugs, the OS of patients with APC remains poor. Until recently, 5-FU was considered one of the standard agents in the treatment of APC and improved therapeutic index was obtained using CI schedule.</offsets></p><p><offsets xml_i="17992" xml_f="18164" txt_i="11559" txt_f="11731">Single-agent GEM is the currently recommended first-line treatment for APC with an RR of 10% (range 5.4–14.3%), median survival of 4.5 months and 1-year survival of 15–18%.</offsets></p><p><offsets xml_i="18171" xml_f="18242" txt_i="11732" txt_f="11803">In a phase III trial, which compared 5-FU bolus with GEM, survival (18 </offsets><italic><offsets xml_i="18250" xml_f="18252" txt_i="11803" txt_f="11805">vs</offsets></italic><offsets xml_i="18261" xml_f="18410" txt_i="11805" txt_f="11954"> 2% at 1 year) and clinical benefit response (24 and 4.4%) were improved in the GEM arm. In a compassionate trial of 3023 patients treated with GEM, </offsets><xref ref-type="other" rid="bib30"><offsets xml_i="18445" xml_f="18455" txt_i="11954" txt_f="11964">Storniolo </offsets><italic><offsets xml_i="18463" xml_f="18468" txt_i="11964" txt_f="11969">et al</offsets></italic><offsets xml_i="18477" xml_f="18484" txt_i="11969" txt_f="11976"> (1999)</offsets></xref><offsets xml_i="18491" xml_f="18587" txt_i="11976" txt_f="12072"> reported a median survival of 5.1 months in chemo-naïve and 3.9 in previously treated patients.</offsets></p><p><italic><offsets xml_i="18602" xml_f="18610" txt_i="12073" txt_f="12081">In vitro</offsets></italic><offsets xml_i="18619" xml_f="18755" txt_i="12081" txt_f="12217"> studies, in HT-29 colon cancer cells, revealed synergy when 5-FU was administered prior to GEM but not with concurrent administration (</offsets><xref ref-type="other" rid="bib29"><offsets xml_i="18790" xml_f="18796" txt_i="12217" txt_f="12223">Shulz </offsets><italic><offsets xml_i="18804" xml_f="18809" txt_i="12223" txt_f="12228">et al</offsets></italic><offsets xml_i="18818" xml_f="18824" txt_i="12228" txt_f="12234">, 1998</offsets></xref><offsets xml_i="18831" xml_f="18833" txt_i="12234" txt_f="12236">; </offsets><xref ref-type="other" rid="bib19"><offsets xml_i="18868" xml_f="18879" txt_i="12236" txt_f="12247">Madajewicz </offsets><italic><offsets xml_i="18887" xml_f="18892" txt_i="12247" txt_f="12252">et al</offsets></italic><offsets xml_i="18901" xml_f="18907" txt_i="12252" txt_f="12258">, 2000</offsets></xref><offsets xml_i="18914" xml_f="19238" txt_i="12258" txt_f="12582">). GEM depletes cellular deoxyuridine monophosphate (dUMP) pools, thereby decreasing competition with 5FdUMP at the target enzyme thymidylate synthase (TS). GEM may also inhibit TS. Finally, 5-FU metabolites may inhibit deoxycytidine monophosphate deaminase, an enzyme responsible for the inactivation of GEM monophosphate (</offsets><xref ref-type="other" rid="bib13"><offsets xml_i="19273" xml_f="19288" txt_i="12582" txt_f="12597">Heinemann, 2002</offsets></xref><offsets xml_i="19295" xml_f="19460" txt_i="12597" txt_f="12762">; GEM-based combination treatment of pancreatic cancer). Preclinical data do not evaluate the different methods of 5-FU administration such as protracted CI therapy </offsets><italic><offsets xml_i="19468" xml_f="19470" txt_i="12762" txt_f="12764">vs</offsets></italic><offsets xml_i="19479" xml_f="19672" txt_i="12764" txt_f="12957"> bolus therapy. 5-FU bolus have reported disappointing results with a median survival of less than 5 months. More prolonged infusion schedules are associated with a median OS time of 6–8 months</offsets></p><p><offsets xml_i="19679" xml_f="19891" txt_i="12958" txt_f="13170">The combination of GEM and 5-FU have been used in a great variety of schedules: 5-FU bolus, CI, standard-dose 5-FU or protracted (24–48 h) infusion of high-dose 5-FU given either at weekly or biweekly intervals (</offsets><xref ref-type="other" rid="bib6"><offsets xml_i="19925" xml_f="19936" txt_i="13170" txt_f="13181">Castellano </offsets><italic><offsets xml_i="19944" xml_f="19949" txt_i="13181" txt_f="13186">et al</offsets></italic><offsets xml_i="19958" xml_f="19964" txt_i="13186" txt_f="13192">, 2000</offsets></xref><offsets xml_i="19971" xml_f="19973" txt_i="13192" txt_f="13194">; </offsets><xref ref-type="other" rid="bib17"><offsets xml_i="20008" xml_f="20015" txt_i="13194" txt_f="13201">Louvet </offsets><italic><offsets xml_i="20023" xml_f="20028" txt_i="13201" txt_f="13206">et al</offsets></italic><offsets xml_i="20037" xml_f="20043" txt_i="13206" txt_f="13212">, 2001</offsets></xref><offsets xml_i="20050" xml_f="20052" txt_i="13212" txt_f="13214">; </offsets><xref ref-type="other" rid="bib20"><offsets xml_i="20087" xml_f="20094" txt_i="13214" txt_f="13221">Maurel </offsets><italic><offsets xml_i="20102" xml_f="20107" txt_i="13221" txt_f="13226">et al</offsets></italic><offsets xml_i="20116" xml_f="20122" txt_i="13226" txt_f="13232">, 2001</offsets></xref><offsets xml_i="20129" xml_f="20131" txt_i="13232" txt_f="13234">).</offsets></p><p><offsets xml_i="20138" xml_f="20220" txt_i="13235" txt_f="13317">Six studies, including 164 patients with APC, have evaluated CI 5-FU (200–250 mg m</offsets><sup><offsets xml_i="20225" xml_f="20227" txt_i="13317" txt_f="13319">−2</offsets></sup><offsets xml_i="20233" xml_f="20237" txt_i="13319" txt_f="13323"> day</offsets><sup><offsets xml_i="20242" xml_f="20244" txt_i="13323" txt_f="13325">−1</offsets></sup><offsets xml_i="20250" xml_f="20284" txt_i="13325" txt_f="13359">) in combination with GEM in APC (</offsets><xref ref-type="other" rid="bib14"><offsets xml_i="20319" xml_f="20327" txt_i="13359" txt_f="13367">Hidalgo </offsets><italic><offsets xml_i="20335" xml_f="20340" txt_i="13367" txt_f="13372">et al</offsets></italic><offsets xml_i="20349" xml_f="20355" txt_i="13372" txt_f="13378">, 1999</offsets></xref><offsets xml_i="20362" xml_f="20364" txt_i="13378" txt_f="13380">; </offsets><xref ref-type="other" rid="bib2"><offsets xml_i="20398" xml_f="20406" txt_i="13380" txt_f="13388">Anchisi </offsets><italic><offsets xml_i="20414" xml_f="20419" txt_i="13388" txt_f="13393">et al</offsets></italic><offsets xml_i="20428" xml_f="20434" txt_i="13393" txt_f="13399">, 2000</offsets></xref><offsets xml_i="20441" xml_f="20443" txt_i="13399" txt_f="13401">; </offsets><xref ref-type="other" rid="bib28"><offsets xml_i="20478" xml_f="20486" txt_i="13401" txt_f="13409">Shulman </offsets><italic><offsets xml_i="20494" xml_f="20499" txt_i="13409" txt_f="13414">et al</offsets></italic><offsets xml_i="20508" xml_f="20514" txt_i="13414" txt_f="13420">, 2000</offsets></xref><offsets xml_i="20521" xml_f="20523" txt_i="13420" txt_f="13422">; </offsets><xref ref-type="other" rid="bib1"><offsets xml_i="20557" xml_f="20565" txt_i="13422" txt_f="13430">Alabiso </offsets><italic><offsets xml_i="20573" xml_f="20578" txt_i="13430" txt_f="13435">et al</offsets></italic><offsets xml_i="20587" xml_f="20593" txt_i="13435" txt_f="13441">, 2001</offsets></xref><offsets xml_i="20600" xml_f="20602" txt_i="13441" txt_f="13443">; </offsets><xref ref-type="other" rid="bib23"><offsets xml_i="20637" xml_f="20643" txt_i="13443" txt_f="13449">Rauch </offsets><italic><offsets xml_i="20651" xml_f="20656" txt_i="13449" txt_f="13454">et al</offsets></italic><offsets xml_i="20665" xml_f="20671" txt_i="13454" txt_f="13460">, 2001</offsets></xref><offsets xml_i="20678" xml_f="20680" txt_i="13460" txt_f="13462">; </offsets><xref ref-type="other" rid="bib24"><offsets xml_i="20715" xml_f="20720" txt_i="13462" txt_f="13467">Reni </offsets><italic><offsets xml_i="20728" xml_f="20733" txt_i="13467" txt_f="13472">et al</offsets></italic><offsets xml_i="20742" xml_f="20748" txt_i="13472" txt_f="13478">, 2001</offsets></xref><offsets xml_i="20755" xml_f="20915" txt_i="13478" txt_f="13638">). Response rate was between 13 and 51%, and OS between 5.3 and 10.3 months. Clinical benefit was only determined in three trials with an RR of 31, 45 and 78% (</offsets><xref ref-type="other" rid="bib14"><offsets xml_i="20950" xml_f="20958" txt_i="13638" txt_f="13646">Hidalgo </offsets><italic><offsets xml_i="20966" xml_f="20971" txt_i="13646" txt_f="13651">et al</offsets></italic><offsets xml_i="20980" xml_f="20986" txt_i="13651" txt_f="13657">, 1999</offsets></xref><offsets xml_i="20993" xml_f="20995" txt_i="13657" txt_f="13659">; </offsets><xref ref-type="other" rid="bib1"><offsets xml_i="21029" xml_f="21037" txt_i="13659" txt_f="13667">Alabiso </offsets><italic><offsets xml_i="21045" xml_f="21050" txt_i="13667" txt_f="13672">et al</offsets></italic><offsets xml_i="21059" xml_f="21065" txt_i="13672" txt_f="13678">, 2001</offsets></xref><offsets xml_i="21072" xml_f="21074" txt_i="13678" txt_f="13680">; </offsets><xref ref-type="other" rid="bib24"><offsets xml_i="21109" xml_f="21114" txt_i="13680" txt_f="13685">Reni </offsets><italic><offsets xml_i="21122" xml_f="21127" txt_i="13685" txt_f="13690">et al</offsets></italic><offsets xml_i="21136" xml_f="21142" txt_i="13690" txt_f="13696">, 2001</offsets></xref><offsets xml_i="21149" xml_f="21152" txt_i="13696" txt_f="13699">). </offsets><xref ref-type="other" rid="bib16"><offsets xml_i="21187" xml_f="21193" txt_i="13699" txt_f="13705">Kurtz </offsets><italic><offsets xml_i="21201" xml_f="21206" txt_i="13705" txt_f="13710">et al</offsets></italic><offsets xml_i="21215" xml_f="21222" txt_i="13710" txt_f="13717"> (2000)</offsets></xref><offsets xml_i="21229" xml_f="21576" txt_i="13717" txt_f="14064">, using GEM plus CI 5-FU, reported an RR of 10 and 42% of stable disease (SD) with a median survival of 4 months. GEM plus CI 5-FU was well tolerated and major toxicities were principally mucositis, nausea/vomiting and leukopenia. The toxicities of CI 5-FU and GEM do not overlap, they can be used in combination at full doses, as demonstrated by </offsets><xref ref-type="other" rid="bib14"><offsets xml_i="21611" xml_f="21619" txt_i="14064" txt_f="14072">Hidalgo </offsets><italic><offsets xml_i="21627" xml_f="21632" txt_i="14072" txt_f="14077">et al</offsets></italic><offsets xml_i="21641" xml_f="21648" txt_i="14077" txt_f="14084"> (1999)</offsets></xref><offsets xml_i="21655" xml_f="21787" txt_i="14084" txt_f="14216">. Recent data from studies comparing GEM with or without 5-FU suggest that 5-FU bolus administration may be of little or no benefit.</offsets></p><p><offsets xml_i="21794" xml_f="21801" txt_i="14217" txt_f="14224">Berlin </offsets><italic><offsets xml_i="21809" xml_f="21814" txt_i="14224" txt_f="14229">et al</offsets></italic><offsets xml_i="21823" xml_f="21970" txt_i="14229" txt_f="14376"> in a randomised trial of 327 patients used GEM alone weekly for 3 weeks out of every 4 weeks or GEM followed by 5-FU weekly on the same schedule (</offsets><xref ref-type="other" rid="bib3"><offsets xml_i="22004" xml_f="22011" txt_i="14376" txt_f="14383">Berlin </offsets><italic><offsets xml_i="22019" xml_f="22024" txt_i="14383" txt_f="14388">et al</offsets></italic><offsets xml_i="22033" xml_f="22039" txt_i="14388" txt_f="14394">, 2002</offsets></xref><offsets xml_i="22046" xml_f="22104" txt_i="14394" txt_f="14452">). The combination arm did not improve the median OS (6.7 </offsets><italic><offsets xml_i="22112" xml_f="22114" txt_i="14452" txt_f="14454">vs</offsets></italic><offsets xml_i="22123" xml_f="22797" txt_i="14454" txt_f="15128"> 5.4 months) compared with GEM alone. The RR were in the range of 5.6 and 6.9% and PFS 2.2 months compared with 3.4 months for the combination. This study did not demonstrate a synergistic activity of this combination with respect to GEM alone. This trial demonstrated that GEM plus 5-FU is a tolerable regimen. Although toxicities were more common on the GEM plus 5-FU arm, there was no significant difference between the two arms. The most common grade 3 and 4 side effects were leukopenia, thrombocytopenia and diarrhoea. Other trials using 5-FU bolus plus GEM reported a median response of 14% (range 3.7–20%) and a median survival of 6.4 months (range 4.4–7.5 months) (</offsets><xref ref-type="other" rid="bib11"><offsets xml_i="22832" xml_f="22840" txt_i="15128" txt_f="15136">Gutzler </offsets><italic><offsets xml_i="22848" xml_f="22853" txt_i="15136" txt_f="15141">et al</offsets></italic><offsets xml_i="22862" xml_f="22868" txt_i="15141" txt_f="15147">, 1999</offsets></xref><offsets xml_i="22875" xml_f="22877" txt_i="15147" txt_f="15149">; </offsets><xref ref-type="other" rid="bib6"><offsets xml_i="22911" xml_f="22922" txt_i="15149" txt_f="15160">Castellano </offsets><italic><offsets xml_i="22930" xml_f="22935" txt_i="15160" txt_f="15165">et al</offsets></italic><offsets xml_i="22944" xml_f="22950" txt_i="15165" txt_f="15171">, 2000</offsets></xref><offsets xml_i="22957" xml_f="22959" txt_i="15171" txt_f="15173">).</offsets></p><p><offsets xml_i="22966" xml_f="23040" txt_i="15174" txt_f="15248">Our research group investigated a combination regimen of GEM plus CI 5-FU </offsets><italic><offsets xml_i="23048" xml_f="23050" txt_i="15248" txt_f="15250">vs</offsets></italic><offsets xml_i="23059" xml_f="23833" txt_i="15250" txt_f="16024"> GEM alone in a randomised phase II trial in APC. The results do not suggest a better activity of combination over GEM alone. The overall RR for all patients treated was 8% in GEM alone and 11% in the combination arm. The evaluation of tumour areas in pancreatic cancer is difficult, even with newer imaging techniques, because of a vigorous desmoplastic reaction, including inflammation and fibrosis within and around the tumour. In the locally advanced pancreatic cancer, we used CT scan to parameter the lesion with two perpendicular diameters, possibly excluding desmoplastic reaction even if there were possible difficulties in accuracy. In this trial, we did not obtain any objective response in the primary tumour. Finally, median TTP and OS are similar in both arms.</offsets></p><p><offsets xml_i="23840" xml_f="24167" txt_i="16025" txt_f="16352">Historical comparisons between clinical trial are hazardous because there is considerable variability between study population, schedule and methodology of response evaluation, although with these considerations in mind the median survival for GEM alone, on GOIRC trial, was better than the principal studies with GEM alone (7 </offsets><italic><offsets xml_i="24175" xml_f="24177" txt_i="16352" txt_f="16354">vs</offsets></italic><offsets xml_i="24186" xml_f="24288" txt_i="16354" txt_f="16456"> 5.7 months). The RR and OS in trials with GEM plus 5-FU bolus ranged from 3.7 to 20% and 5–10 months </offsets><italic><offsets xml_i="24296" xml_f="24298" txt_i="16456" txt_f="16458">vs</offsets></italic><offsets xml_i="24307" xml_f="24366" txt_i="16458" txt_f="16517"> 13–25% and 4–7 months with GEM plus CI 5-FU, respectively.</offsets></p><p><offsets xml_i="24373" xml_f="25070" txt_i="16518" txt_f="17215">The incidence of gastrointestinal grade 3 and 4 toxicities was low in both arms. Haematological toxicity was principally grades 1 and 2; only one patient (2%) developed severe thrombocytopenia. Clinical benefit response, as introduced by Burris, was not measured prospectively in this study. In this trial, patients with disease confined to the pancreas alone (33% in the combination arm and 27% in GEM alone) did not receive radiotherapy. Although the more recent studies suggest a reasonable survival time with CT+RT, the results are not convincingly better than chemotherapy alone. Thus, it follows that it is not clear whether CT+RT confers any survival advantage when compared with CT alone (</offsets><xref ref-type="other" rid="bib21"><offsets xml_i="25105" xml_f="25117" txt_i="17215" txt_f="17227">Neoptolemos </offsets><italic><offsets xml_i="25125" xml_f="25130" txt_i="17227" txt_f="17232">et al</offsets></italic><offsets xml_i="25139" xml_f="25145" txt_i="17232" txt_f="17238">, 2003</offsets></xref><offsets xml_i="25152" xml_f="25398" txt_i="17238" txt_f="17484">). The patients were evaluated for QoL by SCI questionnaire and there were no statistical differences between the two arms, although only a small number of patients received an evaluation for QoL after second cycles due to progression of disease.</offsets></p><p><offsets xml_i="25405" xml_f="25860" txt_i="17485" txt_f="17940">In conclusion, treatment of APC remains a challenge. This trial demonstrated that the addition of CI 5-FU to GEM does not show sufficient activity in order to be further tested in phase III trials. Other trials with several different schedules or modulations of 5-FU do not improve the outcome of pancreatic cancer. A future goal could be represented by the introduction of targeted therapies to improve disease control without significant added toxicity.</offsets></p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alabiso</surname><given-names>O</given-names></name><name><surname>Buosi</surname><given-names>R</given-names></name><name><surname>Clerico</surname><given-names>M</given-names></name><name><surname>Dogliotti</surname><given-names>L</given-names></name><name><surname>Forti</surname><given-names>L</given-names></name><name><surname>Lattuada</surname><given-names>S</given-names></name><name><surname>Merlano</surname><given-names>M</given-names></name><name><surname>Ostellino</surname><given-names>O</given-names></name><name><surname>Satolli</surname><given-names>M</given-names></name><name><surname>Alabiso</surname><given-names>I</given-names></name><name><surname>Sponghini</surname><given-names>A</given-names></name></person-group><article-title>Preliminary results of a phase II study with gemcitabine and continuous infusion 5-FU in patients with advanced or metastatic pancreatic cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2001</year><volume>20</volume><fpage>A2331</fpage></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anchisi</surname><given-names>S</given-names></name><name><surname>Delaloye</surname><given-names>B</given-names></name><name><surname>Petite</surname><given-names>J</given-names></name><name><surname>Laurencet</surname><given-names>FL</given-names></name><name><surname>Ambrod</surname><given-names>CH</given-names></name><name><surname>Obrist</surname><given-names>R</given-names></name></person-group><article-title>Gemcitabine (GEM) and continuous infusional 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>2000</year><volume>19</volume><fpage>A1280H</fpage></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname><given-names>JD</given-names></name><name><surname>Catalano</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>JP</given-names></name><name><surname>Kugler</surname><given-names>JW</given-names></name><name><surname>Haller</surname><given-names>DG</given-names></name><name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name></person-group><article-title>Phase III study of gemcitabine in combination with fluorouracil <italic>vs</italic> gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3270</fpage><lpage>3275</lpage><pub-id pub-id-type="pmid">12149301</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Tarassoff</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name><name><surname>Dorr</surname><given-names>FA</given-names></name><name><surname>Stephens</surname><given-names>CD</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>Improvements in survival and clinical benefit with GEM as first-line therapy for patients with advanced pancreas cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>2413</lpage><pub-id pub-id-type="pmid">9196156</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>TH</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><name><surname>Varkey</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Szatrowski</surname><given-names>TP</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Schulz</surname><given-names>JJ</given-names></name></person-group><article-title>Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">11773165</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Pronk</surname><given-names>L</given-names></name><name><surname>Tornamira</surname><given-names>MV</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Ciruelos</surname><given-names>E</given-names></name><name><surname>Carcas</surname><given-names>A</given-names></name><name><surname>Frias</surname><given-names>J</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name></person-group><article-title>A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing of administration of gemcitabine (G) and folinic acid (FA)/fluorouracil (FU) in advanced pancreatic cancer (APC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2000</year><volume>19</volume><fpage>A1133</fpage></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cullinan</surname><given-names>S</given-names></name><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Wieand</surname><given-names>HS</given-names></name><name><surname>Schutt</surname><given-names>AJ</given-names></name><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Foley</surname><given-names>JF</given-names></name><name><surname>Norris</surname><given-names>BD</given-names></name><name><surname>Kardinal</surname><given-names>CG</given-names></name><name><surname>Tschetter</surname><given-names>LK</given-names></name><name><surname>Barlow</surname><given-names>JF</given-names></name></person-group><article-title>A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin</article-title><source>Cancer</source><year>1990</year><volume>65</volume><fpage>2207</fpage><lpage>2212</lpage><pub-id pub-id-type="pmid">2189551</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cullinan</surname><given-names>SA</given-names></name><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Fleming</surname><given-names>TR</given-names></name><name><surname>Rubin</surname><given-names>JR</given-names></name><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Everson</surname><given-names>LK</given-names></name><name><surname>Windschitl</surname><given-names>HE</given-names></name><name><surname>Twito</surname><given-names>DI</given-names></name><name><surname>Warschke</surname><given-names>RF</given-names></name><name><surname>Foley</surname><given-names>JF</given-names></name></person-group><article-title>A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil <italic>vs</italic> fluorouracil and doxorubicin <italic>vs</italic> fluorouracil, doxorubicin, and mitomycin</article-title><source>JAMA</source><year>1985</year><volume>253</volume><fpage>2061</fpage><lpage>2067</lpage><pub-id pub-id-type="pmid">2579257</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Jacobsson</surname><given-names>G</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name></person-group><article-title>Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><supplement>6</supplement><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">8879373</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenlee</surname><given-names>RT</given-names></name><name><surname>Hill-Harmon</surname><given-names>MB</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA Cancer J Clin</source><year>2001</year><volume>51</volume><fpage>15</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11577478</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutzler</surname><given-names>F</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Hosch</surname><given-names>WP</given-names></name><name><surname>Wagner</surname><given-names>V</given-names></name><name><surname>Nehme</surname><given-names>M</given-names></name><name><surname>Rudi</surname><given-names>J</given-names></name><name><surname>Stremmel</surname><given-names>W</given-names></name></person-group><article-title>A phase I study of gemcitabine (GEM) in combination with five days 5-fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct</article-title><source>Proc Am Soc Clin Oncol</source><year>1999</year><volume>18</volume><fpage>A1097</fpage></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Quebbman</surname><given-names>E</given-names></name><name><surname>Ritch</surname><given-names>P</given-names></name><name><surname>Chitambar</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name></person-group><article-title>Continuous 5-fluorouracil infusion in carcinoma of the pancreas</article-title><source>Am J Med Sci</source><year>1988</year><volume>295</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">3344760</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinemann</surname><given-names>V</given-names></name></person-group><article-title>Gemcitabine-based combination treatment of pancreatic cancer</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><supplement>Suppl 3</supplement><fpage>25</fpage><lpage>35</lpage></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Gravalos</surname><given-names>C</given-names></name><name><surname>Diaz-Puente</surname><given-names>M</given-names></name><name><surname>Hitt</surname><given-names>R</given-names></name><name><surname>Alonso</surname><given-names>S</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name></person-group><article-title>Phase I–II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">10080603</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>HL</given-names></name></person-group><article-title>The pemetrexed/gemcitabine combination in pancreatic cancer</article-title><source>Cancer</source><year>2002</year><volume>15</volume><fpage>928</fpage><lpage>932</lpage></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>JE</given-names></name><name><surname>Kohser</surname><given-names>F</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Trillet-Lenoir</surname><given-names>V</given-names></name><name><surname>Walters</surname><given-names>S</given-names></name><name><surname>Limacher</surname><given-names>JM</given-names></name><name><surname>Untereiner</surname><given-names>M</given-names></name><name><surname>Kayitalire</surname><given-names>L</given-names></name><name><surname>Jaeck</surname><given-names>D</given-names></name><name><surname>Dufour</surname><given-names>P</given-names></name></person-group><article-title>Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study</article-title><source>Hepatogastroenterology</source><year>2000</year><volume>47</volume><supplement>35</supplement><fpage>1450</fpage><lpage>1453</lpage><pub-id pub-id-type="pmid">11100374</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Hammel</surname><given-names>P</given-names></name></person-group><article-title>Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">11432627</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>MP</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Wagener</surname><given-names>T</given-names></name><name><surname>Van Laethem</surname><given-names>J-L</given-names></name><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Wils</surname><given-names>J</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Koene</surname><given-names>C-H</given-names></name><name><surname>Arnaud</surname><given-names>JP</given-names></name><name><surname>Mitry</surname><given-names>E</given-names></name><name><surname>Husseini</surname><given-names>F</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name><name><surname>El-Serafi</surname><given-names>M</given-names></name><name><surname>Etienne</surname><given-names>P</given-names></name><name><surname>Fleeth</surname><given-names>J</given-names></name><name><surname>Lingenfelser</surname><given-names>T</given-names></name><name><surname>Praet</surname><given-names>M</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name></person-group><article-title>Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group</article-title><source>Proc Am Soc Clin Oncol</source><year>2002</year><volume>21</volume><fpage>A498</fpage></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madajewicz</surname><given-names>S</given-names></name><name><surname>Hentschel</surname><given-names>P</given-names></name><name><surname>Burns</surname><given-names>P</given-names></name><name><surname>Caruso</surname><given-names>R</given-names></name><name><surname>Fiore</surname><given-names>J</given-names></name><name><surname>Fried</surname><given-names>M</given-names></name><name><surname>Malhotra</surname><given-names>H</given-names></name><name><surname>Ostrow</surname><given-names>S</given-names></name><name><surname>Sugarman</surname><given-names>S</given-names></name><name><surname>Viola</surname><given-names>M</given-names></name></person-group><article-title>Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies</article-title><source>J Clin Oncol</source><year>2000</year><volume>15</volume><fpage>3553</fpage><lpage>3557</lpage></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maurel</surname><given-names>J</given-names></name><name><surname>García López</surname><given-names>JL</given-names></name><name><surname>Léon</surname><given-names>A</given-names></name><name><surname>Bréton</surname><given-names>J</given-names></name><name><surname>Fernandez Martos</surname><given-names>C</given-names></name><name><surname>Florian</surname><given-names>J</given-names></name><name><surname>Sanchez</surname><given-names>RoviraP</given-names></name><name><surname>Casinello</surname><given-names>J</given-names></name><name><surname>Galan</surname><given-names>M</given-names></name><name><surname>Aranda</surname><given-names>E</given-names></name><name><surname>Llanos</surname><given-names>M</given-names></name><name><surname>Sastre</surname><given-names>J</given-names></name><name><surname>Dorta</surname><given-names>J</given-names></name><name><surname>Carrato</surname><given-names>A</given-names></name></person-group><article-title>Phase II trial of gemcitabine (GEM) and 48-h continuous infusion (CI) of 5-fluorouracil (5-FU) as first-line treatment for patients with locally advanced and metastatic exocrine pancreatic cancer (PC)</article-title><source>Proc Am Soc Clin Oncol</source><year>2001</year><volume>20</volume><fpage>A2290</fpage></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neoptolemos</surname><given-names>JP</given-names></name><name><surname>D Cunningham</surname><given-names>D</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Stocken</surname><given-names>DD</given-names></name><name><surname>Tait</surname><given-names>DM</given-names></name><name><surname>Dunn</surname><given-names>JA</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><name><surname>Lacaine</surname><given-names>F</given-names></name><name><surname>Hickey</surname><given-names>H</given-names></name><name><surname>Raraty</surname><given-names>MG</given-names></name><name><surname>Ghaneh</surname><given-names>P</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name></person-group><article-title>Adjuvant therapy in pancreatic cancer: historical and current perspectives</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>675</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">12702520</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pizzolato</surname><given-names>JF</given-names></name><name><surname>Saltz</surname><given-names>LB</given-names></name></person-group><article-title>Irinotecan in the treatment of pancreatic cancer</article-title><source>Expert Rev Anticancer Ther</source><year>2003</year><volume>3</volume><fpage>587</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">14599083</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>DP</given-names></name><name><surname>Maurer</surname><given-names>CA</given-names></name><name><surname>Aebi</surname><given-names>S</given-names></name><name><surname>Pampallon</surname><given-names>S</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Ludwig</surname><given-names>CU</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Borner</surname><given-names>MM</given-names></name></person-group><article-title>Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer</article-title><source>Oncology</source><year>2001</year><volume>60</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">11150907</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reni</surname><given-names>M</given-names></name><name><surname>Passoni</surname><given-names>P</given-names></name><name><surname>Panucci</surname><given-names>MG</given-names></name><name><surname>Nicoletti</surname><given-names>R</given-names></name><name><surname>Galli</surname><given-names>L</given-names></name><name><surname>Balzano</surname><given-names>G</given-names></name><name><surname>Zerbi</surname><given-names>A</given-names></name><name><surname>Di Carlo</surname><given-names>V</given-names></name><name><surname>Villa</surname><given-names>E</given-names></name></person-group><article-title>Definitive results of a phase II trial of cisplatin, epirubicin, continuous infusion 5-fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>2679</fpage><lpage>2686</lpage><pub-id pub-id-type="pmid">11352960</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Andersen</surname><given-names>JS</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Tarassoff</surname><given-names>PG</given-names></name><name><surname>Brown</surname><given-names>TD</given-names></name><name><surname>Casper</surname><given-names>ES</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>A phase II trial of GEM in patients with 5-FU-refractory pancreas cancer</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">8805925</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schilsky</surname><given-names>RL</given-names></name><name><surname>Bertucci</surname><given-names>D</given-names></name><name><surname>Vogelzang</surname><given-names>NJ</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>582</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">11786589</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>BP</given-names></name><name><surname>Ganjoo</surname><given-names>KN</given-names></name><name><surname>Seitz</surname><given-names>DE</given-names></name><name><surname>Picus</surname><given-names>J</given-names></name><name><surname>Fata</surname><given-names>F</given-names></name><name><surname>Stoner</surname><given-names>C</given-names></name><name><surname>Calley</surname><given-names>C</given-names></name><name><surname>Loehrer</surname><given-names>PJ</given-names></name></person-group><article-title>Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study</article-title><source>Oncology</source><year>2003</year><volume>65</volume><supplement>3</supplement><fpage>218</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">14657595</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>KL</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Lad</surname><given-names>TE</given-names></name><name><surname>Reilly</surname><given-names>K</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Vokes</surname><given-names>E</given-names></name></person-group><article-title>Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FU) in advanced pancreatic cancer: a University of Chicago Phase II Consortium study</article-title><source>Proc Am Soc Clin Oncol</source><year>2000</year><volume>19</volume><fpage>A1126</fpage></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shulz</surname><given-names>L</given-names></name><name><surname>Schalhorm</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>W</given-names></name><name><surname>Heinemann</surname><given-names>V</given-names></name></person-group><article-title>Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells</article-title><source>Am Soc Clin Oncol</source><year>1998</year><volume>17</volume><fpage>A965</fpage></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Enas</surname><given-names>NH</given-names></name><name><surname>Brown</surname><given-names>CA</given-names></name><name><surname>Voi</surname><given-names>M</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Schilsky</surname><given-names>R</given-names></name></person-group><article-title>An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma</article-title><source>Cancer</source><year>1999</year><volume>85</volume><supplement>6</supplement><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">10189130</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamburini</surname><given-names>M</given-names></name><name><surname>Brambilla</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>L</given-names></name><name><surname>Bombino</surname><given-names>T</given-names></name><name><surname>Gangler</surname><given-names>L</given-names></name><name><surname>Rosso</surname><given-names>S</given-names></name></person-group><article-title>Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving chemotherapy for operable breast cancer</article-title><source>Ann Oncol</source><year>1991</year><volume>2</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">1768628</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinerman</surname><given-names>BH</given-names></name><name><surname>MacCormick</surname><given-names>RE</given-names></name></person-group><article-title>A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin <italic>vs</italic> a matched tumor registry control population</article-title><source>Am J Clin Oncol</source><year>1994</year><volume>17</volume><supplement>6</supplement><fpage>467</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">7977161</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Survival curves estimated by the Kaplan–Meier method: <italic>Y</italic>-axis, probability of survival; <italic>X</italic>-axis, weeks.</p></caption><graphic mime-subtype="jpeg" xlink:href="93-6602640f1"></graphic></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="left"></col><col align="center"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" charoff="50"><bold>GEM</bold></th><th colspan="2" align="center" valign="top" charoff="50"><bold>GEM+CI 5-FU</bold></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Characteristics</bold></th><th align="center" valign="top" charoff="50"><bold>No.</bold></th><th align="left" valign="top" charoff="50"><bold>(%)</bold></th><th align="center" valign="top" charoff="50"><bold>No.</bold></th><th align="left" valign="top" charoff="50"><bold>(%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Enrolled</td><td align="center" valign="top" charoff="50">49</td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">45</td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50">Evaluable</td><td align="center" valign="top" charoff="50">48</td><td align="left" valign="top" charoff="50">98</td><td align="center" valign="top" charoff="50">43</td><td align="left" valign="top" charoff="50">96</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"><italic>Median age (years)</italic> (range)</td><td align="center" valign="top" charoff="50">64 (34–75)</td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">62 (44–75)</td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"> Gender</td></tr><tr><td align="left" valign="top" charoff="50">  Male</td><td align="center" valign="top" charoff="50">23</td><td align="left" valign="top" charoff="50">48</td><td align="center" valign="top" charoff="50">27</td><td align="left" valign="top" charoff="50">63</td></tr><tr><td align="left" valign="top" charoff="50">  Female</td><td align="center" valign="top" charoff="50">25</td><td align="left" valign="top" charoff="50">52</td><td align="center" valign="top" charoff="50">16</td><td align="left" valign="top" charoff="50">37</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>PS (Karnofsky)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> ⩾80</td><td align="center" valign="top" charoff="50">33</td><td align="left" valign="top" charoff="50">69</td><td align="center" valign="top" charoff="50">29</td><td align="left" valign="top" charoff="50">67</td></tr><tr><td align="left" valign="top" charoff="50"> &lt;80</td><td align="center" valign="top" charoff="50">15</td><td align="left" valign="top" charoff="50">31</td><td align="center" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">33</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Previous surgery</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Yes</td><td align="center" valign="top" charoff="50">21</td><td align="left" valign="top" charoff="50">44</td><td align="center" valign="top" charoff="50">17</td><td align="left" valign="top" charoff="50">40</td></tr><tr><td align="left" valign="top" charoff="50"> No</td><td align="center" valign="top" charoff="50">27</td><td align="left" valign="top" charoff="50">56</td><td align="center" valign="top" charoff="50">26</td><td align="left" valign="top" charoff="50">60</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Site of disease</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Pancreas alone</td><td align="center" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">27</td><td align="center" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">33</td></tr><tr><td align="left" valign="top" charoff="50"> Pancreas+liver</td><td align="center" valign="top" charoff="50">28</td><td align="left" valign="top" charoff="50">58</td><td align="center" valign="top" charoff="50">20</td><td align="left" valign="top" charoff="50">47</td></tr><tr><td align="left" valign="top" charoff="50"> Pancreas+nodes</td><td align="center" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">13</td><td align="center" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50"> Others</td><td align="center" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="left" valign="top" charoff="50"> </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Disease at presentation</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Locally advanced</td><td align="center" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">27</td><td align="center" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">33</td></tr><tr><td align="left" valign="top" charoff="50"> Metastatic disease</td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">73</td><td align="center" valign="top" charoff="50">29</td><td align="left" valign="top" charoff="50">67</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label></label><p>GEM=gemcitabine; CI=continuous infusion; 5-FU=5-fluorouracil; PS=performance status.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Grade of adverse effects by treatment group</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="3" align="center" valign="top" charoff="50"><bold>GEM, <italic>N</italic>=49</bold></th><th colspan="3" align="center" valign="top" charoff="50"><bold>GEM+CI 5-FU, <italic>N</italic>=41</bold></th></tr><tr><th align="left" valign="top" charoff="50"> </th><th colspan="6" align="center" valign="top" charoff="50"><bold>Grade (WHO)</bold></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Type of toxicity</bold></th><th align="center" valign="top" charoff="50"><bold>1+2</bold></th><th align="center" valign="top" charoff="50"><bold>3</bold></th><th align="center" valign="top" charoff="50"><bold>4</bold></th><th align="center" valign="top" charoff="50"><bold>1+2</bold></th><th align="center" valign="top" charoff="50"><bold>3</bold></th><th align="center" valign="top" charoff="50"><bold>4</bold></th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Hematological</italic></td></tr><tr><td align="left" valign="top" charoff="50"> WBC</td><td align="center" valign="top" charoff="50">28 (57%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">17 (41%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Haemoglobin</td><td align="center" valign="top" charoff="50">24 (49%)</td><td align="center" valign="top" charoff="50">3 (6%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">14 (34%)</td><td align="center" valign="top" charoff="50">3 (7%)</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Platelets</td><td align="center" valign="top" charoff="50">7 (14%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">8 (20%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">1 (2%)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Nonhaematological</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Nausea/vomiting</td><td align="center" valign="top" charoff="50">21 (43%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">13 (32%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Mucositis</td><td align="center" valign="top" charoff="50">7 (14%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">12 (29%)</td><td align="center" valign="top" charoff="50">2 (5%)</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Diarrhoea</td><td align="center" valign="top" charoff="50">2 (4%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">8 (20%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Asthenia</td><td align="center" valign="top" charoff="50">20 (41%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">13 (32%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50"> Fever</td><td align="center" valign="top" charoff="50">9 (18%)</td><td align="center" valign="top" charoff="50">1 (2%)</td><td align="center" valign="top" charoff="50">—</td><td align="center" valign="top" charoff="50">7 (17%)</td><td align="center" valign="top" charoff="50">2 (5%)</td><td align="center" valign="top" charoff="50">—</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label></label><p>GEM=gemcitabine; CI=continuous infusion; 5-FU=5-fluorouracil.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Objective response rate, duration of response, PFS and survival data</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold></th><th align="left" valign="top" charoff="50"><bold>GEM, <italic>n</italic> (%)</bold></th><th align="left" valign="top" charoff="50"><bold>GEM+CI 5-FU, <italic>n</italic> (%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Evaluable patients</td><td align="left" valign="top" charoff="50">48</td><td align="left" valign="top" charoff="50">43</td></tr><tr><td align="left" valign="top" charoff="50">CR</td><td align="left" valign="top" charoff="50">—</td><td align="left" valign="top" charoff="50">—</td></tr><tr><td align="left" valign="top" charoff="50">PR</td><td align="left" valign="top" charoff="50">4 (8%)</td><td align="left" valign="top" charoff="50">5 (11%)</td></tr><tr><td align="left" valign="top" charoff="50">(95% confidence interval)</td><td align="left" valign="top" charoff="50">(0.5–16%)</td><td align="left" valign="top" charoff="50">(2–22%)</td></tr><tr><td align="left" valign="top" charoff="50">SD</td><td align="left" valign="top" charoff="50">14 (29%)</td><td align="left" valign="top" charoff="50">12 (28%)</td></tr><tr><td align="left" valign="top" charoff="50">PR+SD</td><td align="left" valign="top" charoff="50">18 (37%)</td><td align="left" valign="top" charoff="50">17 (39%)</td></tr><tr><td align="left" valign="top" charoff="50">PD</td><td align="left" valign="top" charoff="50">30 (63%)</td><td align="left" valign="top" charoff="50">26 (61%)</td></tr><tr><td align="left" valign="top" charoff="50">Median duration response (range)</td><td align="left" valign="top" charoff="50">34 weeks (25–101)</td><td align="left" valign="top" charoff="50">26 weeks (16–46)</td></tr><tr><td align="left" valign="top" charoff="50">Median PFS (range)</td><td align="left" valign="top" charoff="50">14 weeks (2–65)</td><td align="left" valign="top" charoff="50">18 weeks (4–51)</td></tr><tr><td align="left" valign="top" charoff="50">Median OS (range)</td><td align="left" valign="top" charoff="50">31 weeks (1–101)</td><td align="left" valign="top" charoff="50">30 weeks (1–101)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote3"><label></label><p>PFS=progression free survival; CR=complete response; PR=partial response; SD=stable disease; PD=progression disease.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>